Tizedon-MR
Generic Name
Trimetazidine Dihydrochloride Modified Release
Manufacturer
Biopharma Limited
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| trizedon mr 35 mg tablet | ৳ 8.00 | ৳ 80.00 |
Description
Overview of the medicine
Tizedon-MR 35 mg Tablet contains Trimetazidine Dihydrochloride, a cytoprotective anti-ischemic agent. It works by optimizing myocardial metabolism and improving energy efficiency in cells under ischemic conditions, thus reducing symptoms of angina pectoris.
Uses & Indications
Dosage
Adults
One 35 mg modified-release tablet twice daily, i.e., once in the morning and once in the evening, during meals.
Elderly
No specific dose adjustment is required in elderly patients with normal renal function. Close monitoring is recommended for elderly patients with moderate renal impairment.
Renal_impairment
For patients with moderate renal impairment (creatinine clearance 30-60 mL/min), the recommended dose is one 35 mg modified-release tablet in the morning during breakfast.
How to Take
Oral administration. Tablets should be swallowed whole with a glass of water, during meals. Do not chew or crush.
Mechanism of Action
Trimetazidine inhibits 3-ketoacyl-CoA thiolase (3-KAT), an enzyme involved in fatty acid oxidation. This shifts myocardial energy production towards glucose oxidation, which is more efficient in ischemic conditions, requiring less oxygen. It maintains cellular ATP levels and reduces intracellular acidosis.
Pharmacokinetics
Onset
Within 15 days of treatment for symptomatic improvement.
Excretion
Primarily via urine, mainly unchanged.
Half life
Approximately 7 hours for standard release; prolonged for MR (around 12-14 hours).
Absorption
Rapidly and almost completely absorbed after oral administration. Cmax reached in approximately 2 hours for standard release, but prolonged for MR.
Metabolism
Minimal metabolism.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Parkinson's disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders.
- Severe renal impairment (creatinine clearance <30 mL/min).
Drug Interactions
No significant drug interactions have been reported.
Trimetazidine is not known to interact significantly with other drugs.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited experience with overdose. Treatment should be symptomatic and supportive. Gastric lavage and activated charcoal may be considered if ingestion is recent.
Pregnancy & Lactation
Pregnancy: Limited data. Not recommended during pregnancy unless essential. Lactation: It is unknown whether trimetazidine is excreted in human milk. A risk to the suckling child cannot be excluded. Therefore, Tizedon-MR should not be used during breast-feeding.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Parkinson's disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders.
- Severe renal impairment (creatinine clearance <30 mL/min).
Drug Interactions
No significant drug interactions have been reported.
Trimetazidine is not known to interact significantly with other drugs.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited experience with overdose. Treatment should be symptomatic and supportive. Gastric lavage and activated charcoal may be considered if ingestion is recent.
Pregnancy & Lactation
Pregnancy: Limited data. Not recommended during pregnancy unless essential. Lactation: It is unknown whether trimetazidine is excreted in human milk. A risk to the suckling child cannot be excluded. Therefore, Tizedon-MR should not be used during breast-feeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Usually 24 to 36 months from manufacturing date.
Availability
Available in pharmacies nationwide
Approval Status
Approved in many countries for angina and other cardiac conditions.
Patent Status
Off-patent
Clinical Trials
Numerous clinical trials have demonstrated the efficacy and safety of trimetazidine in patients with stable angina pectoris, showing improvement in exercise tolerance and reduction in angina attacks.
Lab Monitoring
- No specific routine lab monitoring required. Renal function may be monitored in patients with pre-existing renal impairment.
Doctor Notes
- Carefully assess patients for Parkinson's disease or other movement disorders before initiating trimetazidine.
- Monitor for worsening or new movement disorders during treatment.
- Dose adjustment required for moderate renal impairment.
Patient Guidelines
- Take the tablet exactly as prescribed by your doctor.
- Do not stop taking the medicine abruptly without consulting your doctor.
- Inform your doctor about any pre-existing medical conditions, especially Parkinson's disease or renal problems.
- Report any new or worsening movement disorders to your doctor immediately.
Missed Dose Advice
If a dose is missed, take the next dose at the usual time. Do not take a double dose to make up for a missed one.
Driving Precautions
This medicine may cause dizziness and visual disturbances, which could affect the ability to drive or operate machinery. Patients should be advised to exercise caution.
Lifestyle Advice
- Maintain a healthy diet and regular exercise as advised by your doctor.
- Avoid smoking and excessive alcohol consumption.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.